News

Orphazyme’s arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis

Dec 18, 2019

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today received Fast Track designation from the US Food and Drug Administration (FDA) for the development of arimoclomol for the treatment of sporadic Inclusion Body Myositis (sIBM). 

Orphazyme s arimoclomol receives us fast track ...

Read more

Major shareholder announcement

Nov 28, 2019

Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of November 27, 2019 holds a total 999,606 shares in the Company, corresponding to 5.00% of the share capital and that Danske Bank as of November 27, 2019 controls 7.53% of the voting rights in the Company.

Major shareholder announcement

Read more

Orphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC)

Nov 19, 2019

Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for arimoclomol, an investigational drug for the treatment of Niemann-Pick Disease Type C (NPC).

Orphazyme receives breakthrough therapy designation

Read more

Financial calendar 2020

Nov 1, 2019

Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the company expects to publish financial reports according to the following schedule.

Financial calendar 2020

Read more

Major shareholder announcement

Oct 2, 2019

Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of October 1, 2019 holds a total 998,962 shares in the Company, corresponding to 4.99% of the share capital and that Danske Bank as of October 1, 2019 controls 7.74% of the voting rights in the Company.

Major shareholder announcement

Read more

Orphazyme CMO to speak at FDA-funded rare disease data analytics platform launch event

Sep 17, 2019

Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, has been invited to participate in a meeting hosted by the National Organization for Rare Disorders (NORD) and the Critical Path Institute (C-PATH) to launch their joint initiative: the Rare Disease Cures Accelerator Data and Analytics Platform (RDCA-DAP). Funded by the US Food and Drug Administration (FDA), the goal of RDCA-DAP is to accelerate the process of moving therapies from bench to bedside for rare diseases. 

Orphazyme cmo to speak at fda funded rare disease...

Read more

Orphazyme announces Interim Report First Half 2019

Aug 28, 2019

Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces its interim financial results for the period January 1 – June 30, 2019 and corporate highlights.

Orphazyme announces interim report first half 2019

Interim report first half 2019

Read more

Orphazyme strengthens balance sheet with EUR 9 million financing from Kreos Capital

Aug 27, 2019

Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has entered into a structured debt facility (Loan Agreement) with Kreos Capital VI (UK) Limited (Kreos) to secure funding of EUR 9 million. Orphazyme plans to draw down the loan on September 1, 2019. Proceeds from the loan will be used to fund the on-going preparations for filing of arimoclomol in the US and Europe, commercial planning, and for general corporate purposes. 

Orphazyme strengthens balance sheet with eur 9 milli

Read more

Orphazyme Interim Report First Half 2019 Presentation

Aug 21, 2019

Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the Company will be hosting an investor call at which Chief Executive Officer, Anders Hinsby, and Chief Financial Officer, Anders Vadsholt, will be presenting the Interim Report First Half 2019. The presentation will be followed by a Q&A session.

Orphazyme interim report first half 2019 presentation

Read more

Major shareholder announcement

Aug 5, 2019

Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of 2 August 2019 holds a total 1,022,154 shares in the Company, corresponding to 5.11% of the share capital and that Danske Bank as of 2 August 2019 controls 7.86% of the voting rights in the Company.

Orphazyme major shareholder announcement

Read more

1 ... 19 20 21 22 23 24